Investor Update

Basel, 22 August 2019

Tecentriq, an Anti-PD-L1 Antibody, Receives Approval for Additional Indication of Extensive-Stage Small Cell Lung Cancer

Dear Investor,

Please find attached a press release by Chugai.

Do not hesitate to contact us for any further questions.